Novo Nordisk speeds up obesity plans and maintains ambitious target for obesity candidate
Novo Nordisk now expects to submit its candidate semaglutide for approval against obesity around the turn of the year. Meanwhile, the company's chief research officer maintains significant weight loss target for the company's obesity candidate AM833.
BY KEVIN GRØNNEMANN & RITZAU FINANS
It will be a shorter than expected wait before Novo Nordisk submits its versatile drug semaglutide for approval against obesity, says Mads Krogsgaard Thomsen, CSO at Novo Nordisk.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
